Skip to main content

Medicine supply to Northern Ireland to receive further scrutiny

16 January 2023

The Protocol on Ireland/Northern Ireland Sub-Committee takes evidence from pharmaceutical industry representatives as it launches a follow-up investigation into the impact of the Protocol on the provision of medicines to Northern Ireland.


In autumn 2021, against the backdrop of fears that some companies may decide no longer to supply medicines to Northern Ireland, the Committee undertook a short inquiry into the provision of medicines under the Protocol and wrote to the Government setting out its findings. The Committee is now launching this follow-up work to discuss how the situation has evolved since 2021, including following the adoption of legislative changes by the EU and the Northern Ireland MHRA Authorised Route (NIMAR) put in place by the UK. The Committee will take further evidence on 25 January from other leading industry representatives.


Wednesday 18 January at 3:15pm
Room 4, Palace of Westminster

  • Michelle Riddalls, Chief Executive, PAGB, the consumer healthcare association
  • Martin Sawer, Executive Director, Healthcare Distribution Association
  • Paul Williams, Senior Director Corporate Affairs, Teva UK

Possible questions

  • What are the main issues facing the pharmaceutical industry in terms of medicine supply to Northern Ireland under the Protocol as it is currently operating?
  • How has industry adapted or changed its operating model as a result of the Protocol?
  • Does the Protocol carry any current or potential beneficial effects from the point of view of medicine provision to Northern Ireland?
  • What changes, if any, have taken place in relation to the scale of cross-border supply of medicines on the island of Ireland since the Protocol came into force?
  • What has been the impact of the EU’s legislation on medicines, announced in December 2021 and in force since April 2022, including on the scale of product withdrawal from Northern Ireland?
  • What are the main outstanding issues to be resolved relating to the supply of medicines, including i) the Centralised Procedure ii) the application of the Falsified Medicines Directive and iii) the supply of medical devices to Northern Ireland?
  • Is the Northern Ireland MHRA Authorised Route (NIMAR) working effectively?
  • What impact will the Northern Ireland Protocol Bill, including the proposed dual regulatory regime, have on the supply of medicines in Northern Ireland?
  • What impact will future regulatory divergence between Great Britain and the EU have on medicine supply to Northern Ireland, and how can this be addressed?
  • How are the UK and the EU engaging with industry regarding outstanding issues requiring resolution?
  • What, in your view, is the best way forward to resolve the outstanding issues?

Further information